Marc Bastow

Marc Bastow

Marc Bastow is Assistant Editor at InvestorPlace.com. He earned a Bachelor of Arts from the University of Connecticut and a Masters in Finance from American University. Bastow worked in corporate banking and finance, and he most recently was Senior Editor at MocoSportsFan.com.

Recent Articles

Can Gap Dethrone Lululemon as Queen of Fitness Chic?

Wherever Lululemon goes Gap's Athleta stores follow, as they fight for a share of the women's active apparel market. Here's how their stocks compare.

3 CEOs Who Might’ve Opted Out Early

If these three CEOs had been given a chance to just walk away scot-free after a few weeks, they might have just done it.

All Earnings, All the Time — Thursday’s IP Market Recap

Tech stocks ruled the day as strong earnings in the sector and across the board helped lift markets to gains Thursday.

From the Media Big Six, I’ll Pick Mickey

Media consolidation means just a handful of giants own nearly all the content you view and read. For me, picking one stock is a matter of taste -- my taste.

Tech Takes Over the Market — Wednesday’s IP Market Recap

Tech stocks rallied despite a warning from Intel, leading the Nasdaq to gains of more than 1%, and eBay, IBM and Qualcomm were on the rise late.

Memo to Marissa Mayer, Re: Turnarounds

Turnarounds are exceedingly tough to pull off -- but not quite impossible. For inspiration, Yahoo's new(est) CEO should look no further than these three examples.

Earnings Outyell Bernanke — Tuesday IP Market Recap

Despite non-comments by Fed chairman Ben Bernanke, markets finished the day in the black, led by earnings-driven gains in Coca-Cola, Goldman and others.

Berkshire Hathaway’s Premium: Confidence

Berkshire Hathaway shares have marched to 52-week highs as investors continue to believe in the succession preparation efforts of Warren Buffett.

Retail Results Spoil the Day — Monday’s IP Market Recap

A disappointing retail report and mixed results for Citigroup's second quarter weighed on markets Monday, though M&A news sparked life into pharma.

HGSI Holdout Proves Profitable — for Bagels

Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.